• 1
    Crompton G (2006) A brief history of inhaled asthma therapy over the last fifty years. Primary Care Respiratory Journal, 15, 326331.
  • 2
    Cameron SJ, Cooper EJ, Crompton GK, Hoare MV, Grant IW (1973) Substitution of beclomethasone aerosol for oral prednisolone in the treatment of chronic asthma. British Medical Journal, 4, 205207.
  • 3
    Hodson ME, Batten JC, Clarke SW, Gregg I (1974) Beclomethasone dipropionate aerosol in asthma. Transfer of steroid-dependent asthmatic patients from oral prednisone to beclomethasone dipropionate aerosol. The American Review of Respiratory Disease, 110, 403408.
  • 4
    Vilsvik JS, Schaanning J (1974) Beclomethasone dipropionate aerosol in adult steroid-dependent obstructive lung disease. Scandinavian Journal of Respiratory Disease, 55, 169175.
  • 5
    National Heart Lung and Blood Institute (2007) Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, US Department of Health and Human Services.
  • 6
    Adcock IM, Ito K (2004) Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue? Current Opinion in Pharmacology, 4, 257262.
  • 7
    Barnes PJ (2006) Corticosteroids: the drugs to beat. European Journal of Pharmacology, 533, 214.
  • 8
    Chanez P, Wenzel SE, Anderson GP et al. (2007) Severe asthma in adults: what are the important questions? Journal of Allergy and Clinical Immunology, 119, 13371348.
  • 9
    Leach CL, Davidson PJ, Boudreau RJ (1998) Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. European Respiratory Journal, 12, 13461353.
  • 10
    Willey RF, Milne LJ, Crompton GK, Grant IW (1976) Beclomethasone dipropionate aerosol and oropharyngeal candidiasis. British Journal of Diseases of the Chest, 70, 3238.
  • 11
    Kennedy WA, Laurier C, Gautrin D et al. (2000) Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. Journal of Clinical Epidemiology, 53, 696701.
  • 12
    Roland NJ, Bhalla RK, Earis J (2004) The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest, 126, 213219.
  • 13
    Buhl R (2006) Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy, 61, 518526.
  • 14
    Selroos O, Backman R, Forsen KO et al. (1994) Local side-effects during 4-year treatment with inhaled corticosteroids – a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy, 49, 888890.
  • 15
    Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK (1995) Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. European Respiratory Journal, 8, 590592.
  • 16
    Dubus J-C, Mely L, Huiart L, Marguet C, Le Roux P (2003) Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundamental and Clinical Pharmacology, 17, 627631.
  • 17
    Lipworth BJ (1999) Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Archives of Internal Medicine, 159, 941955.
  • 18
    Weiner P, Berar-Yanay N, Davidovich A, Magadle R (1999) Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest, 116, 931934.
  • 19
    Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A (1994) An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. British Journal of Clinical Pharmacology, 38, 521525.
  • 20
    White M, Crisalida T, Li H, Economides A, Kaliner M (2006) Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma. Annals of Allergy, Asthma, and Immunology, 96, 437444.
  • 21
    Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D (2002) Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Archives of Disease in Childhood, 87, 457461.
  • 22
    Autio P, Karjalainen J, Risteli L, Risteli J, Kiistala U, Oikarinen A (1996) Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. American Journal of Respiratory and Critical Care Medicine, 153, 11721175.
  • 23
    Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY (1990) Purpura and dermal thinning associated with high dose inhaled corticosteroids. British Medical Journal, 300, 15481551.
  • 24
    Tashkin DP, Murray HE, Skeans M, Murray RP (2004) Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest, 126, 11231133.
  • 25
    Mak VH, Melchor R, Spiro SG (1992) Easy bruising as a side-effect of inhaled corticosteroids. European Respiratory Journal, 5, 10681074.
  • 26
    Pauwels RA, Lofdahl CG, Laitinen LA et al. (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 340, 19481953.
  • 27
    Roy A, Leblanc C, Paquette L et al. (1996) Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. European Respiratory Journal, 9, 226231.
  • 28
    Egan JJ, Maden C, Kalra S, Adams JE, Eastell R, Woodcock AA (1999) A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. European Respiratory Journal, 13, 12671275.
  • 29
    Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S (1995) Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 96, 571579.
  • 30
    Herrala J, Puolijoki H, Impivaara O, Liippo K, Tala E, Nieminen MM (1994) Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. Bone, 15, 621623.
  • 31
    Marystone JF, Barrett-Connor EL, Morton DJ (1995) Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. American Journal of Public Health, 85, 16931695.
  • 32
    Kerstjens HA, Postma DS, Van Doormaal JJ et al. (1994) Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax, 49, 652656.
  • 33
    Pouw EM, Prummel MF, Oosting H, Roos CM, Endert E (1991) Beclomethasone inhalation decreases serum osteocalcin concentrations. British Medical Journal, 302, 627628.
  • 34
    Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR (1991) Inhaled corticosteroids, bone formation, and osteocalcin. Lancet, 338, 6061.
  • 35
    Wong CA, Walsh LJ, Smith CJP et al. (2000) Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet, 355, 13991403.
  • 36
    Kelly HW, Nelson HS (2003) Potential adverse effects of the inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 112, 469478 (quiz 79).
  • 37
    Rossi GA, Cerasoli F, Cazzola M (2007) Safety of inhaled corticosteroids: room for improvement. Pulmonary Pharmacology & Therapeutics, 20, 2335.
  • 38
    Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K (2004) Safety of inhaled corticosteroids. Proceedings of the American Thoracic Society, 1, 171175.
  • 39
    Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane database of systematic reviews (Online), CD003537.
  • 40
    Toogood JH, Markov AE, Baskerville J, Dyson C (1993) Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. Journal of Allergy and Clinical Immunology, 91, 571579.
  • 41
    Cumming RG, Mitchell P, Leeder SR (1997) Use of inhaled corticosteroids and the risk of cataracts. New England Journal of Medicine, 337, 814.
  • 42
    Smeeth L, Boulis M, Hubbard R, Fletcher AE (2003) A population based case–control study of cataract and inhaled corticosteroids. British Journal of Ophthalmology, 87, 12471251.
  • 43
    Uboweja A, Malhotra S, Pandhi P (2006) Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis. Fundamental and Clinical Pharmacology, 20, 305309.
  • 44
    Garbe E, LeLorier J, Boivin JF, Suissa S (1997) Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA, 277, 722727.
  • 45
    Samiy N, Walton DS, Dreyer EB (1996) Inhaled steroids: effect on intraocular pressure in patients without glaucoma. Canadian Journal of Ophthalmology, 31, 120123.
  • 46
    Sin DD, Tu JV (2001) Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. European Respiratory Journal, 17, 380385.
  • 47
    Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. European Journal of Respiratory Diseases. Supplement, 122, 8695.
  • 48
    Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N (2001) Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. British Journal of Clinical Pharmacology, 51, 400409.
  • 49
    Derendorf H (2007) Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. Journal of Clinical Pharmacology, 47, 782789.
  • 50
    Thorsson L, Dahlström K, Edsbäcker S, Kallén A, Paulson J, Wirén JE (1997) Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. British Journal of Clinical Pharmacology, 43, 155161.
  • 51
    Nave R, Bethke TD, Van Marle SP, Zech K (2004) Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clinical Pharmacokinetics, 43, 479486.
  • 52
    Hübner M, Hochhaus G, Derendorf H (2005) Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunology and allergy clinics of North America, 25, 469488.
  • 53
    Tunek A, Sjodin K, Hallstrom G (1997) Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metabolism and Disposition, 25, 13111317.
  • 54
    Hubbard WC, Blum AE, Bickel CA, Heller NM, Schleimer RP (2003) Detection and quantitation of fatty acid acyl conjugates of triamcinolone acetonide via gas chromatography–electron-capture negative-ion mass spectrometry. Analytical Biochemistry, 322, 243250.
  • 55
    Nave R, Meyer W, Fuhst R, Zech K (2005) Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulmonary Pharmacology & Therapeutics, 18, 390396.
  • 56
    Mutch E, Nave R, McCracken N, Zech K, Williams FM (2007) The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochemical Pharmacology, 73, 16571664.
  • 57
    Rohatagi S, Arya V, Zech K et al. (2003) Population pharmacokinetics and pharmacodynamics of ciclesonide. Journal of Clinical Pharmacology, 43, 365378.
  • 58
    Adams N, Bestall J, Jones PW (2001) Budesonide at different doses for chronic asthma. Cochrane database of systematic reviews (Online), CD003271.
  • 59
    Adams NP, Jones PW (2006) The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respiratory Medicine, 100, 12971306.
  • 60
    Bateman E, Karpel J, Casale T, Wenzel S, Banerji D (2006) Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest, 129, 11761187.
  • 61
    Meltzer EO, Wenzel S (2006) The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. Journal of Asthma, 43, 765772.
  • 62
    Fish JE, Karpel JP, Craig TJ et al. (2000) Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. Journal of Allergy and Clinical Immunology, 106, 852860.
  • 63
    Larsen JS, Hahn M, Ekholm B, Wick KA (1994) Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. Journal of Asthma, 31, 193199.
  • 64
    Guidry GG, Brown WD, Stogner SW, George RB (1992) Incorrect use of metered dose inhalers by medical personnel. Chest, 101, 3133.
  • 65
    Thorsson L, Geller D (2005) Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide. Respiratory Medicine, 99, 836849.
  • 66
    Cates CJ, Bestall J, Adams N (2006) Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane database of systematic reviews (Online), CD001491.
  • 67
    Dolovich MB (2002) Aeorsol delivery devices and airways/lung deposition. In: SchleimerRP, O’ByrnePM, SzeflerSJ, BrattsandR, eds. Aeorsol delivery devices and airways/lung deposition. Basel: Marcel Dekker, 169212.
  • 68
    Olsson B (1995) Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? Journal of Aerosol Medicine, 8(Suppl. 3), S13S18 (discussion S19).
  • 69
    Borgström L, Asking L, Thorsson L (2005) Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. International Journal of Clinical Practice, 59, 14881495.
  • 70
    Thomas M, Williams AE (2005) Are outcomes the same with all dry powder inhalers? International Journal of Clinical Practice, 59 (Suppl 149), 3335.
  • 71
    Frew AJ, Langley SJ, Perrin V, Hertog MG (2002) Effects of 4-week treatment with low-dose budesonide (100 micrograms BID) from a novel inhaler Airmax and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma. Respiratory Medicine, 96, 542547.
  • 72
    Dahlström K, Thorsson L, Larsson P, Nikander K (2003) Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Annals of Allergy, Asthma, and Immunology, 90, 226232.
  • 73
    Thorsson L, Edsbacker S, Conradson TB (1994) Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. European Respiratory Journal, 7, 18391844.
  • 74
    Dolovich MB, Ahrens RC, Hess DR et al. (2005) Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest, 127, 335371.
  • 75
    Bodor N, Buchwald P (2006) Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Current Pharmaceutical Design, 12, 32413260.
  • 76
    Biggadike K, Uings I, Farrow SN (2004) Designing corticosteroid drugs for pulmonary selectivity. Proceedings of the American Thoracic Society, 1, 352355.
  • 77
    Dickens GR, Wermeling DP, Matheny CJ et al. (2000) Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Annals of Allergy, Asthma, and Immunology, 84, 528532.
  • 78
    Mollmann H, Wagner M, Krishnaswami S et al. (2001) Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. Journal of Clinical Pharmacology, 41, 13291338.
  • 79
    Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W (2006) Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal, 28, 10421050.
  • 80
    Crim C, Pierre LN, Daley-Yates PT (2001) A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clinical Therapeutics, 23, 13391354.
  • 81
    Tayab ZR, Fardon TC, Lee DKC et al. (2007) Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. British Journal of Clinical Pharmacology, 64, 698705.
  • 82
    Valotis A, Neukam K, Elert O, Högger P (2004) Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. Journal of Pharmaceutical Sciences, 93, 13371350.
  • 83
    Belvisi MG, Bundschuh DS, Stoeck M et al. (2005) Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. Journal of Pharmacology and Experimental Therapeutics, 314, 568574.
  • 84
    Jaffuel D, Demoly P, Gougat C et al. (2000) Transcriptional potencies of inhaled glucocorticoids. American Journal of Respiratory and Critical Care Medicine, 162, 5763.